JAAD onlineCutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
References (5)
- et al.
Pulmonary sarcoid-like granulomatosis induced by ipilimumab
J Clin Oncol
(2012) - et al.
Anti-CTLA-4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient
Dermatol
(2009)
Cited by (67)
Liver Pathology Related to Onco-Therapeutic Agents
2023, Surgical Pathology ClinicsDermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
2020, Journal of the American Academy of DermatologyCitation Excerpt :Because lesions may be clinically or radiographically concerning for cancer recurrence, an accurate diagnosis is imperative.29,93 Cutaneous presentation varies from solitary to multiple erythematous to brown papules, plaques, or nodules on the trunk, extremities, or head and neck.89-92 Prior scars may be involved.92,95,97
Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma
2020, Autoimmunity ReviewsCitation Excerpt :Categorical variables were analyzed using the Chi-square test and, quantitative variables were analyzed with ANOVA or the Kruskal-Wallis test when appropriate. Ninety-eight patients diagnosed with sarcoidosis/SLR under immunotherapy with CTLA-4, PD-1 or BRAF/MEK inhibitors prescribed were included in this paper [24–90]. Seven patients suffered from suspected sarcoidosis but did not achieve the diagnosis with histologic confirmation and did not include the inclusion criteria so they were excluded from further analyses.
Immune checkpoint inhibitors and the development of granulomatous reactions
2019, Journal of the American Academy of DermatologyCitation Excerpt :The initial literature search yielded a total of 1133 articles. In 56 articles published between 2009 and 2018, there were 59 patients with sarcoid-like GRs (Table I6-54) and 13 patients with other GRs (Table II28,55-62) including granulomatous panniculitis (n = 4), GA (n = 4), granulomatous dermatitis (GD) (n = 4), and granulomatous foreign body reaction (n = 1). The median age of patients with sarcoidosis-like reactions (SLRs) was 59 years (range, 26-83 years), with a slight female predominance (55.5% [30 of 59]).
Systemic Therapies for Advanced Melanoma
2019, Dermatologic Clinics
Funding sources: None.
Conflicts of interest. None declared.